Contributions of leukocyte angiotensin-converting enzyme to development of atherosclerosis

Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2075-80. doi: 10.1161/ATVBAHA.113.301777. Epub 2013 Jul 11.

Abstract

Objective: This study determined the role of angiotensin-converting enzyme (ACE) on the development of angiotensin I-induced atherosclerosis and the contribution of leukocyte-specific expression of this enzyme.

Approach and results: To define the contribution of ACE-dependent activity to angiotensin II synthesis in atherosclerotic development, male low-density lipoprotein receptor(-/-) mice were fed a fat-enriched diet and infused with either angiotensin I or angiotensin II. The same infusion rate of these peptides had equivalent effects on atherosclerotic development. Coinfusion of an ACE inhibitor, enalapril, ablated angiotensin I-augmented atherosclerosis but had no effect on angiotensin II-induced lesion development. ACE protein was detected in several cell types in atherosclerotic lesions, with a predominance in macrophages. This cell type secreted angiotensin II, which was ablated by ACE inhibition. To study whether leukocyte ACE contributed to atherosclerosis, irradiated male low-density lipoprotein receptor(-/-) mice were repopulated with bone marrow-derived cells from either ACE(+/+) or ACE(-/-) mice and fed the fat-enriched diet for 12 weeks. Chimeric mice with ACE deficiency in bone marrow-derived cells had modestly reduced atherosclerotic lesions in aortic arches but had no effects in aortic roots.

Conclusions: ACE mediates angiotensin I-induced atherosclerosis, and ACE expression in leukocytes modestly contributes to atherosclerotic development in hypercholesterolemic mice.

Keywords: angiotensin-converting enzyme inhibitors; angiotensins; atherosclerosis; hypercholesterolemia; macrophages; renin.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Angiotensin I / administration & dosage
  • Angiotensin I / metabolism*
  • Angiotensin II / administration & dosage
  • Angiotensin II / metabolism*
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage
  • Animals
  • Atherosclerosis / enzymology*
  • Atherosclerosis / genetics
  • Atherosclerosis / pathology
  • Atherosclerosis / prevention & control
  • Bone Marrow Transplantation
  • Cells, Cultured
  • Diet, High-Fat
  • Disease Models, Animal
  • Enalapril / administration & dosage
  • Hypercholesterolemia / complications
  • Hypercholesterolemia / enzymology
  • Hypercholesterolemia / genetics
  • Leukocytes / drug effects
  • Leukocytes / enzymology*
  • Macrophages / enzymology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Peptidyl-Dipeptidase A / deficiency
  • Peptidyl-Dipeptidase A / genetics
  • Peptidyl-Dipeptidase A / metabolism*
  • Receptors, LDL / deficiency
  • Receptors, LDL / genetics
  • Transplantation Chimera

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Receptors, LDL
  • Angiotensin II
  • Enalapril
  • Angiotensin I
  • Peptidyl-Dipeptidase A